BeiGene, Ltd. logo
BeiGene, Ltd. BGNE
report update icon

Quarterly report 2026-Q3
added 11-05-2026

BeiGene, Ltd. Market Cap | BGNE

As of November 22, 2026 BeiGene, Ltd. has a market cap of $ 251 B


Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]

Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.

This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.

Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.

Annual Market Cap BeiGene, Ltd.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- 253 B 217 B 291 B 293 B 347 B 9.22 B 7.01 B 5.64 B 1.35 B - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
347 B 1.35 B 158 B

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.

Market Cap of other stocks in the Biotechnology industry

Issuer Market Cap Price % 24h Market Cap Country
Daré Bioscience Daré Bioscience
DARE
16.9 M $ 0.41 -9.93 % $ 4.58 M usaUSA
Fate Therapeutics Fate Therapeutics
FATE
187 M $ 0.92 -9.07 % $ 109 M usaUSA
Greenwich LifeSciences Greenwich LifeSciences
GLSI
386 M $ 19.09 -3.54 % $ 258 M usaUSA
Halozyme Therapeutics Halozyme Therapeutics
HALO
9.66 B $ 91.28 -1.89 % $ 10.9 B usaUSA
Hutchison China MediTech Limited Hutchison China MediTech Limited
HCM
12 B $ 13.18 -2.04 % $ 11.3 B chinaChina
Aptorum Group Limited Aptorum Group Limited
APM
6.69 M - - $ 5.72 M chinaChina
iBio iBio
IBIO
142 M $ 0.83 3.01 % $ 86.4 M usaUSA
Kodiak Sciences Kodiak Sciences
KOD
2.03 B $ 97.05 -0.87 % $ 5.16 B usaUSA
Karyopharm Therapeutics Karyopharm Therapeutics
KPTI
45.1 K $ 0.02 -56.5 % $ 219 usaUSA
FSD Pharma FSD Pharma
HUGE
50.7 M - 5743.5 % $ 69.7 M canadaCanada
BioAtla BioAtla
BCAB
5.86 M $ 1.74 0.64 % $ 102 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
3.04 B - - $ 3.85 B usaUSA
UroGen Pharma Ltd. UroGen Pharma Ltd.
URGN
924 M $ 28.91 -8.89 % $ 1.39 B israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
999 M $ 13.01 0.74 % $ 1.16 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
484 M - 1052.0 % $ 415 M usaUSA
ADiTx Therapeutics ADiTx Therapeutics
ADTX
36.6 K - - $ 374 usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
14.8 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
29.1 M - -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
724 M - - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
19.6 M - 1.93 % $ 17.4 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
38.2 M - 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
13.1 M - 4.14 % $ 49.1 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
2.77 B - - $ 5.18 B usaUSA
Athira Pharma Athira Pharma
ATHA
1.62 M - - $ 269 M usaUSA
AVROBIO AVROBIO
AVRO
1.61 M - 1083.1 % $ 745 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
115 B - - $ 96.9 B britainBritain
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
6.33 M - -2.5 % $ 5.88 M usaUSA
EyePoint Pharmaceuticals EyePoint Pharmaceuticals
EYPT
1.15 M $ 0.23 -12.11 % $ 16.8 K usaUSA
Bio-Path Holdings Bio-Path Holdings
BPTH
7.76 M - - $ 100 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
4.51 M - -3.03 % $ 260 M usaUSA
ChromaDex Corporation ChromaDex Corporation
CDXC
431 M - -0.88 % $ 598 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
3.58 M - -16.75 % $ 25.8 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
5.58 K - -5.98 % $ 34.1 M usaUSA
Diffusion Pharmaceuticals Diffusion Pharmaceuticals
DFFN
11.7 M - 11.68 % $ 8.97 M usaUSA
Eloxx Pharmaceuticals Eloxx Pharmaceuticals
ELOX
48.3 M - -5.68 % $ 8.28 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
1.44 M - - $ 40.5 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
561 M - - $ 661 M usaUSA
Evofem Biosciences Evofem Biosciences
EVFM
3.86 M - 7.55 % $ 38.1 M usaUSA
Eyenovia Eyenovia
EYEN
800 K - 49.81 % $ 13.2 M usaUSA
FibroGen FibroGen
FGEN
180 M - - $ 889 M usaUSA
Homology Medicines Homology Medicines
FIXX
76.3 M - 0.77 % $ 53.4 M usaUSA
Amicus Therapeutics Amicus Therapeutics
FOLD
4.43 B - - $ 4.47 B usaUSA
Frequency Therapeutics Frequency Therapeutics
FREQ
22.9 M - - $ 528 M usaUSA
Galecto Galecto
GLTO
935 K - - $ 762 M danmarkDanmark
GlycoMimetics GlycoMimetics
GLYC
18.1 M - 9357.83 % $ 1.01 B usaUSA
Graybug Vision Graybug Vision
GRAY
1.97 M - -11.23 % $ 9.65 M usaUSA
Galera Therapeutics Galera Therapeutics
GRTX
7.65 M - -32.59 % $ 7.61 M usaUSA
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
8.91 M - 1.35 % $ 17.8 M chinaChina
Novavax Novavax
NVAX
1.85 B $ 7.47 -3.24 % $ 1.21 B usaUSA